Including DPYD on Cancer Genetic Panels to Prevent Fatal Fluoropyrimidine Toxicity

Authors: Daniel L. Hertz PharmD, PhD and Vaibhav Sahai MBBS, MS
View More View Less
Restricted access

Disclosures: The authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Daniel L. Hertz, PharmD, PhD, Department of Clinical Pharmacy, University of Michigan College of Pharmacy, 1100 North University Building, Room 2560C, Ann Arbor, MI 48109-1065. Email: DLHertz@med.umich.edu
  • 1.

    Benson AB III, Venook AP, Al-Hawary M, . NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 2.

    Benson AB III, Venook AP, Al-Hawary M, . NCCN Clinical Practice Guidelines in Oncology: Rectal Cancer. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 3.

    Tempero MA, Malafa MP, Al-Hawary M, . NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 4.

    Benson AB III, D’Angelica MI, Abbott DE, . NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 4.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 5.

    Ajani JA, D’Amico TA, Bentrem DJ, . NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 4.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 6.

    Pfister DG, Spencer S, Adelstein D, . NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 7.

    Armstrong DK, Alvarez RD, Bakkum-Gomez, . NCCN Clinical Practice Guidelines in Oncology: Ovarian Cancer. Version 3.2019. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 8.

    Gradishar WJ, Anderson BO, Abraham J, . NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 3.2020. Accessed February 21, 2020. To view the most recent version, visit NCCN.org.

  • 9.

    Meulendijks D, Henricks LM, Sonke GS, . Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:16391650.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Amstutz U, Henricks LM, Offer SM, . Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 2018;103:210216.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Rai K, Batukbhai BDO, Brooks GA. Risk of treatment-related death in carriers of pathogenic DPYD polymorphisms treated with fluoropyrimidine chemotherapy: a systematic review and patient-level analysis [abstract]. J Clin Oncol 2019;37(Suppl):Abstract e15132.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Institute of Medicine. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington, DC: The National Academies Press; 2012.

  • 13.

    Deenen MJ, Meulendijks D, Cats A, . Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016;34:227234.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Henricks LM, Lunenburg CATC, de Man FM, . DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol 2018;19:14591467.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 15.

    Sepulveda AR, Hamilton SR, Allegra CJ, . Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J Clin Oncol 2017;35:14531486.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 16.

    Labianca R, Nordlinger B, Beretta GD, . Early colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013;24(Suppl 6):vi6472.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Toffoli G, Innocenti F, Polesel J, . The genotype for DPYD risk variants in patients with colorectal cancer and the related toxicity management costs in clinical practice. Clin Pharmacol Ther 2019;105:9941002.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Hertz DL, Glatz A, Pasternak AL, . Integration of germline pharmacogenetics into a tumor sequencing program [published online July 23, 2018]. JCO Precis Oncol, doi: 10.1200/PO.18.00011

    • Crossref
    • Export Citation
  • 19.

    Daly MB, Pilarski R, Berry MP, . NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 3.2019. Accessed June 27, 2019. To view the most recent version, visit NCCN.org.

  • 20.

    Neben CL, Zimmer AD, Stedden W, . Multi-gene panel testing of 23,179 individuals for hereditary cancer risk identifies pathogenic variant carriers missed by current genetic testing guidelines. J Mol Diagn 2019;21:646657.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1131 1131 77
PDF Downloads 425 425 19
EPUB Downloads 0 0 0